Opportunities to Address Gaps in Early Detection and Improve Outcomes of Liver Cancer.

Death rates from primary liver cancer (hepatocellular carcinoma, HCC), have continued to rise in the U.S. over recent decades despite the availability of an increasing range of treatment modalities, including new systemic therapies. Prognosis is strongly associated with tumor stage at diagnosis; however, most cases of HCC are diagnosed beyond an early stage. This lack of early detection has contributed to low survival rates. Professional society guidelines recommend semi-annual ultrasound-based HCC screening for at-risk populations, yet HCC surveillance continues to be underutilized in clinical practice. On April 28, 2022, the Hepatitis B Foundation convened a workshop to discuss the most pressing challenges and barriers to early HCC detection and the need to better leverage existing and emerging tools and technologies that could improve HCC screening and early detection. In this commentary we summarize technical, patient-, provider-, and system-level challenges, and opportunities to improve processes and outcomes across the HCC screening continuum. We highlight promising approaches to HCC risk stratification and screening, including new biomarkers, advanced imaging incorporating AI, and algorithms for risk stratification. Workshop participants emphasized that action to improve early detection and reduce HCC mortality is urgently needed, noting concern that many of the challenges we are facing today are the same or similar to those faced a decade ago, and that HCC mortality rates have not meaningfully improved. Increasing the uptake of HCC screening was identified as a short-term priority, while simultaneously developing and validating better screening tests and risk-appropriate surveillance strategies.